Nautilus Biotechnology (NASDAQ:NAUT) Price Target Raised to $4.00 at Guggenheim

Nautilus Biotechnology (NASDAQ:NAUT) had its target price lifted by Guggenheim from $2.50 to $4.00 in a research report sent to investors on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Wall Street Zen raised Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $4.00.

Nautilus Biotechnology Price Performance

Shares of Nautilus Biotechnology stock remained flat at $2.42 on Friday. The stock had a trading volume of 139,243 shares, compared to its average volume of 213,537. The company has a fifty day moving average of $2.16 and a 200 day moving average of $1.58. The stock has a market capitalization of $305.66 million, a price-to-earnings ratio of -5.15 and a beta of 1.49. Nautilus Biotechnology has a one year low of $0.62 and a one year high of $3.08.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its earnings results on Thursday, February 26th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. On average, equities analysts anticipate that Nautilus Biotechnology will post -0.57 earnings per share for the current year.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of hedge funds have recently bought and sold shares of NAUT. Garde Capital Inc. bought a new stake in shares of Nautilus Biotechnology in the 4th quarter worth $35,000. Hudson Bay Capital Management LP purchased a new position in Nautilus Biotechnology during the fourth quarter worth about $37,000. Ashton Thomas Private Wealth LLC bought a new stake in Nautilus Biotechnology in the 3rd quarter worth about $38,000. Qube Research & Technologies Ltd purchased a new stake in Nautilus Biotechnology in the 2nd quarter valued at about $45,000. Finally, Virtu Financial LLC lifted its position in shares of Nautilus Biotechnology by 19.6% during the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after buying an additional 3,849 shares in the last quarter. 50.71% of the stock is owned by hedge funds and other institutional investors.

Key Nautilus Biotechnology News

Here are the key news stories impacting Nautilus Biotechnology this week:

• Positive Sentiment: Guggenheim raised its price target to $4.00 from $2.50 and initiated/maintained a “buy” rating, implying ~65% upside from the recent price — this analyst action likely supported buying interest. Guggenheim price-target raise
• Positive Sentiment: Q4 2025 results beat expectations on the bottom line: Nautilus reported EPS of ($0.11) vs. consensus ($0.14), and management highlighted strategic progress on its platform and early-access customers — the beat and commentary support a constructive near-term outlook. Earnings release and call
• Neutral Sentiment: Management’s earnings call and published transcripts emphasized “strategic advances” and commercial progress (early-access program ramp), which are positive developments but still early-stage—impact depends on successful scale-up and conversion to sustained revenue. Earnings call transcript
• Negative Sentiment: Nautilus guided to 15%–20% expense growth in 2026 as it scales the early-access program — higher operating spend will widen losses near-term and raises execution risk if commercialization or customer uptake lags expectations. Expense guidance article

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.